ZA993938B - Ziprasidone formulations. - Google Patents

Ziprasidone formulations.

Info

Publication number
ZA993938B
ZA993938B ZA9903938A ZA993938A ZA993938B ZA 993938 B ZA993938 B ZA 993938B ZA 9903938 A ZA9903938 A ZA 9903938A ZA 993938 A ZA993938 A ZA 993938A ZA 993938 B ZA993938 B ZA 993938B
Authority
ZA
South Africa
Prior art keywords
ziprasidone
formulations
ziprasidone formulations
Prior art date
Application number
ZA9903938A
Other languages
English (en)
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA993938(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA993938B publication Critical patent/ZA993938B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
ZA9903938A 1998-06-15 1999-06-14 Ziprasidone formulations. ZA993938B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (1)

Publication Number Publication Date
ZA993938B true ZA993938B (en) 2000-12-14

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9903938A ZA993938B (en) 1998-06-15 1999-06-14 Ziprasidone formulations.

Country Status (45)

Country Link
US (1) US6150366A (xx)
EP (1) EP0965343B1 (xx)
JP (2) JP3441676B2 (xx)
KR (1) KR100338915B1 (xx)
CN (1) CN1307994C (xx)
AP (1) AP1216A (xx)
AR (1) AR015553A1 (xx)
AT (1) ATE240732T1 (xx)
AU (1) AU753820B2 (xx)
BG (1) BG64691B1 (xx)
BR (1) BR9902268A (xx)
CA (1) CA2274338C (xx)
CO (1) CO5070579A1 (xx)
CY (1) CY2003002I1 (xx)
CZ (1) CZ297954B6 (xx)
DE (1) DE69908021T2 (xx)
DK (1) DK0965343T3 (xx)
EA (1) EA002223B1 (xx)
ES (1) ES2197581T3 (xx)
GT (1) GT199900080A (xx)
HK (1) HK1024184A1 (xx)
HN (1) HN1999000089A (xx)
HR (1) HRP990193B1 (xx)
HU (1) HU226487B1 (xx)
ID (1) ID23546A (xx)
IL (1) IL130424A (xx)
IS (1) IS2182B (xx)
MA (1) MA26647A1 (xx)
MY (1) MY121397A (xx)
NO (1) NO316713B1 (xx)
NZ (1) NZ336271A (xx)
OA (1) OA11064A (xx)
PA (1) PA8475601A1 (xx)
PE (1) PE20000632A1 (xx)
PL (2) PL195606B1 (xx)
PT (1) PT965343E (xx)
RS (1) RS49611B (xx)
SG (1) SG77243A1 (xx)
SI (1) SI0965343T1 (xx)
SK (1) SK286245B6 (xx)
TR (1) TR199901379A2 (xx)
TW (1) TW590774B (xx)
UA (1) UA59383C2 (xx)
UY (1) UY25649A1 (xx)
ZA (1) ZA993938B (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
CN1196486C (zh) * 1999-05-27 2005-04-13 辉瑞产品公司 齐普拉西酮悬浮液
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
EP1628973A2 (en) * 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005054235A1 (en) * 2003-11-28 2005-06-16 Wockhardt Limited Process for the preparing ziprasidone monohydrochloride hydrate
JP2007514001A (ja) 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態ｂ２
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
ES2334800T3 (es) * 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
AU2005244151A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
CA2577852A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
CN101166514A (zh) * 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
PT1884242E (pt) 2005-05-26 2013-05-21 Dainippon Sumitomo Pharma Co Composição farmacêutica compreendendo lurasidona
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007062228A1 (en) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
HUE027168T2 (en) 2010-02-25 2016-10-28 Bristol Myers Squibb Co Apixaban formulations
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
MA37714A1 (fr) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Méthodes de traitement de la surcharge pondérale et de l'obésité
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT790236E (pt) * 1996-02-13 2004-04-30 Pfizer Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed

Also Published As

Publication number Publication date
BR9902268A (pt) 2000-05-02
PE20000632A1 (es) 2000-07-26
IS2182B (is) 2006-12-15
EP0965343A2 (en) 1999-12-22
CA2274338C (en) 2003-04-15
EA199900467A2 (ru) 1999-12-29
CZ212799A3 (cs) 2000-09-13
HU9901960D0 (en) 1999-08-30
CN1307994C (zh) 2007-04-04
MA26647A1 (fr) 2004-12-20
RS49611B (sr) 2007-06-04
EP0965343B1 (en) 2003-05-21
EA199900467A3 (ru) 2000-04-24
US6150366A (en) 2000-11-21
OA11064A (en) 2002-03-13
SI0965343T1 (en) 2003-10-31
ES2197581T3 (es) 2004-01-01
AP1216A (en) 2003-10-19
YU27199A (sh) 2002-12-10
HRP990193A2 (en) 2000-02-29
HRP990193B1 (en) 2003-08-31
PL195209B1 (pl) 2007-08-31
NO992892L (no) 1999-12-16
GT199900080A (es) 2000-11-29
UA59383C2 (uk) 2003-09-15
JP2002003492A (ja) 2002-01-09
AU753820B2 (en) 2002-10-31
NO992892D0 (no) 1999-06-14
AU3398399A (en) 1999-12-23
PL195606B1 (pl) 2007-10-31
BG103489A (en) 2000-07-31
PA8475601A1 (es) 2000-09-29
MY121397A (en) 2006-01-28
CZ297954B6 (cs) 2007-05-09
AR015553A1 (es) 2001-05-02
DE69908021D1 (de) 2003-06-26
SK76999A3 (en) 2000-12-11
TR199901379A2 (xx) 2000-01-21
TW590774B (en) 2004-06-11
HK1024184A1 (en) 2000-10-05
AP9901579A0 (en) 1999-06-30
CO5070579A1 (es) 2001-08-28
HN1999000089A (es) 1999-11-03
HU226487B1 (en) 2009-03-02
CA2274338A1 (en) 1999-12-15
EP0965343A3 (en) 2000-02-23
ID23546A (id) 2000-05-04
UY25649A1 (es) 2000-02-23
JP2000007566A (ja) 2000-01-11
ATE240732T1 (de) 2003-06-15
IS5079A (is) 1999-12-16
PT965343E (pt) 2003-08-29
PL333737A1 (en) 1999-12-20
NO316713B1 (no) 2004-04-13
CN1242987A (zh) 2000-02-02
JP4187423B2 (ja) 2008-11-26
HUP9901960A2 (hu) 2000-08-28
CY2003002I1 (el) 2009-11-04
SK286245B6 (sk) 2008-06-06
HUP9901960A3 (en) 2000-09-28
SG77243A1 (en) 2000-12-19
KR100338915B1 (ko) 2002-05-30
NZ336271A (en) 2000-10-27
BG64691B1 (bg) 2005-12-30
JP3441676B2 (ja) 2003-09-02
DK0965343T3 (da) 2003-08-04
IL130424A0 (en) 2000-06-01
EA002223B1 (ru) 2002-02-28
DE69908021T2 (de) 2003-11-27
KR20000006143A (ko) 2000-01-25
IL130424A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ZA993938B (en) Ziprasidone formulations.
ZA996185B (en) Sulfanylsilanes.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200005136B (en) Dihydropyrimides.
ZA993338B (en) Pharmaceutical formulations.
HK1040060A1 (en) Sustained release ranolazine formulations.
MXPA02001088A (es) 2-pirazolin-5-onas..
ZA200108000B (en) Cosmetic compounds.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
ZA200101637B (en) Cyclone.
ZA200202537B (en) Pour-on-formulations.
HK1038884A1 (en) Medicinal compositions.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA200001416B (en) Pesticidal compositions.
HK1040488A1 (en) Pharmaceutical formulations.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA993123B (en) Trisresorcinyltriazines.
ZA991769B (en) Tray.
ZA991892B (en) Herbicidal compositions.
GB0029720D0 (en) I.S machine7544232001
ZA200204581B (en) Nitro-sulfobenzamides.
HK1031254A1 (en) Tachogragh.
EG24008A (en) Ziprasidone formulations
EG23327A (en) Metraplant "iucd".